APLMW (Apollomics) Total Operating Expense: $17.69 Mil (TTM As of Dec. 2025)


APLMW Apollomics Inc APLMW
31 GF Score
Price $0.01
! 5 Warning Signs
View Full Analysis

What is Apollomics Total Operating Expense?

Apollomics APLMW 31 Total Operating Expense is $17.69 Mil as of Dec. 2025. GuruFocus rates APLMW with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

Apollomics's Total Operating Expense for the six months ended in Dec. 2025 was $-1.41 Mil. Apollomics's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was $17.69 Mil.

Apollomics Total Operating Expense Related Terms

Apollomics Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Apollomics's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Apollomics Total Operating Expense Chart

Apollomics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial 50.27 44.39 54.37 42.03 17.69

Apollomics Semi-Annual Data
Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only 28.20 27.08 14.95 19.11 -1.41
APLMW
31GF Score
Apollomics Inc APLMW
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Apollomics Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was $17.69 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of $17.69 Mil mean?
Apollomics (APLMW) has a Total Operating Expense of $17.69 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on Apollomics and its competitors.
Is Apollomics' Total Operating Expense too high?
Apollomics' current Total Operating Expense is $17.69 Mil. Overall, Apollomics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Apollomics' Total Operating Expense compare to HYPD and MGX?
Apollomics' Total Operating Expense of $17.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Apollomics and its competitors. Apollomics's current Total Operating Expense is $17.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apollomics stock overvalued right now?
Apollomics (APLMW) has a current Total Operating Expense of $17.69 Mil. The current Total Operating Expense is $17.69 Mil. Apollomics' overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Apollomics (APLMW), the current Total Operating Expense is $17.69 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Apollomics Business Description

Other Exchanges APLM:USA
Address 989 East Hillsdale Boulevard, Suite 220, Foster, CA, USA, 94404
Apollomics Inc is an clinical-stage biopharmaceutical company focused on the discovery and development of oncology therapies with the potential to be combined with other treatment options to harness the immune system and target specific molecular pathways to inhibit cancer. The company programs include vebreltinib (APL-101), selective c-Met inhibitor for the treatment of non-small cell lung cancer and other tumors with c-Met alterations, and uproleselan (APL-106), a specific E-Selectin antagonist that has the potential to be used adjunctively with standard chemotherapy to treat acute myeloid leukemia. Company has three new immuno-oncology product candidates: APL-501, APL-502 and APL-801 include mono-specific and bi-specific antibodies to fight against cancer.
31GF Score

Get the complete analysis for APLMW

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.01
Price